CA2959670C - Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm - Google Patents

Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm Download PDF

Info

Publication number
CA2959670C
CA2959670C CA2959670A CA2959670A CA2959670C CA 2959670 C CA2959670 C CA 2959670C CA 2959670 A CA2959670 A CA 2959670A CA 2959670 A CA2959670 A CA 2959670A CA 2959670 C CA2959670 C CA 2959670C
Authority
CA
Canada
Prior art keywords
nen
expression level
gep
biomarkers
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2959670A
Other languages
English (en)
French (fr)
Other versions
CA2959670A1 (en
Inventor
Irvin Mark MODLIN
Mark Kidd
Ignat Drozdov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clifton Life Sciences LLC
Original Assignee
Clifton Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clifton Life Sciences LLC filed Critical Clifton Life Sciences LLC
Publication of CA2959670A1 publication Critical patent/CA2959670A1/en
Application granted granted Critical
Publication of CA2959670C publication Critical patent/CA2959670C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2959670A 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm Active CA2959670C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050465P 2014-09-15 2014-09-15
US62/050,465 2014-09-15
PCT/US2015/050274 WO2016044330A1 (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Publications (2)

Publication Number Publication Date
CA2959670A1 CA2959670A1 (en) 2016-03-24
CA2959670C true CA2959670C (en) 2024-02-20

Family

ID=54207775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2959670A Active CA2959670C (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Country Status (13)

Country Link
US (4) US10407730B2 (cg-RX-API-DMAC7.html)
EP (2) EP3194618B1 (cg-RX-API-DMAC7.html)
JP (2) JP6782700B2 (cg-RX-API-DMAC7.html)
KR (2) KR102762958B1 (cg-RX-API-DMAC7.html)
CN (1) CN107208132A (cg-RX-API-DMAC7.html)
AU (3) AU2015317893B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959670C (cg-RX-API-DMAC7.html)
DK (2) DK3929303T3 (cg-RX-API-DMAC7.html)
ES (2) ES3013599T3 (cg-RX-API-DMAC7.html)
IL (2) IL250867B (cg-RX-API-DMAC7.html)
MX (2) MX386919B (cg-RX-API-DMAC7.html)
PL (2) PL3194618T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016044330A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407730B2 (en) 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
MX2019014026A (es) * 2017-05-25 2020-08-03 Liquid Biopsy Res Llc Metodos para la deteccion de melanoma.
CN118910259A (zh) * 2017-11-30 2024-11-08 液体活检研究有限责任公司 使用基因表达测定预测肽受体放射治疗
CN108048564B (zh) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 人glt8d1基因的新用途
US11948296B2 (en) * 2018-07-30 2024-04-02 Agency For Science, Technology And Research Method and system for assessing fibrosis in a tissue sample
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
FR3110764B1 (fr) 2020-05-20 2024-05-10 Quantum Surgical Méthode de prédiction de la récidive d’une lésion par analyse d’images
CN113215255B (zh) * 2021-04-26 2022-04-05 山东天川精准医疗科技有限公司 用于肝癌早期诊断或预后的生物标记物及其用途
CN120153081A (zh) * 2022-07-15 2025-06-13 埃门多生物公司 Aplp2安全港位点敲入策略
CN120380169A (zh) * 2022-09-30 2025-07-25 液体活检研究有限责任公司 用于在唾液中检测神经内分泌癌的方法
CN117292755B (zh) * 2023-08-09 2026-02-06 郑州大学 多模态临界边生物标志物识别方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084883A1 (en) 2003-08-25 2005-04-21 The Johns Hopkins University School Of Medicine Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differential gene expression analysis
JP5728380B2 (ja) * 2008-06-12 2015-06-03 シンタクシン リミテッドSyntaxin Limited 神経内分泌疾患の抑制
AU2012223288B2 (en) 2011-03-01 2017-03-30 Yale University Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
US10407730B2 (en) 2014-09-15 2019-09-10 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Also Published As

Publication number Publication date
AU2015317893A1 (en) 2017-03-23
US20260043085A1 (en) 2026-02-12
JP7157788B2 (ja) 2022-10-20
KR20170045365A (ko) 2017-04-26
IL281355B (en) 2022-02-01
JP2021019618A (ja) 2021-02-18
IL281355A (en) 2021-04-29
KR20250021631A (ko) 2025-02-13
US20220325351A1 (en) 2022-10-13
AU2021212151A1 (en) 2021-08-26
MX386919B (es) 2025-03-19
PL3194618T3 (pl) 2021-12-13
BR112017005279A2 (pt) 2017-12-12
CA2959670A1 (en) 2016-03-24
DK3929303T3 (da) 2025-03-03
AU2023258444A1 (en) 2023-11-23
MX2017003370A (es) 2017-11-22
US10407730B2 (en) 2019-09-10
EP3194618A1 (en) 2017-07-26
US11168372B2 (en) 2021-11-09
US20190345568A1 (en) 2019-11-14
AU2015317893B2 (en) 2021-05-20
AU2021212151B2 (en) 2023-08-03
EP3929303A1 (en) 2021-12-29
JP6782700B2 (ja) 2020-11-11
CN107208132A (zh) 2017-09-26
PL3929303T3 (pl) 2025-04-28
US12258633B2 (en) 2025-03-25
EP3194618B1 (en) 2021-04-21
MX2021012347A (es) 2021-10-22
IL250867A0 (en) 2017-04-30
JP2017528164A (ja) 2017-09-28
DK3194618T3 (da) 2021-07-12
WO2016044330A1 (en) 2016-03-24
EP3929303B1 (en) 2024-12-04
ES3013599T3 (en) 2025-04-14
KR102762958B1 (ko) 2025-02-04
IL250867B (en) 2021-03-25
ES2881474T3 (es) 2021-11-29
US20160076106A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
US12258633B2 (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
US11746380B2 (en) Classification and prognosis of cancer
US9988684B2 (en) Predicting gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
JP2020150949A (ja) メラノーマ癌の予後予測
US20210233611A1 (en) Classification and prognosis of prostate cancer
WO2007073220A9 (en) Prognosis prediction for colorectal cancer
JP2024519082A (ja) 肝細胞がんのdnaメチル化バイオマーカー
CN111315897A (zh) 用于黑素瘤检测的方法
HK40066027B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
HK40066027A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
HK1241416B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
BR112017005279B1 (pt) Métodos para detectar um neoplasma neuroendócrino gastroenteropancreático (gep-nen), para diferenciar gep-nen estável de um gep-nen progressivo e para determinar uma resposta a uma terapia com radionucleotídeo para receptor de peptídeo de um gep-nen

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200911

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240912

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240912

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250901

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909